Global Pet Cancer Therapeutics Market
Global Pet Cancer Therapeutics Market was valued at USD 270.3 million in 2021 and is expected to reach 738.3 million by 2027, at a CAGR 10.5% from 2022-2027.
Pet cancer therapeutics defined as the novel drug molecules which exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program like targeted therapy & combination therapy/chemotherapy depending on the type of cancer, stage, and nature of the cancer.
Market Drivers
The increase in research and development initiatives for cancer management is expected to boost the growth of global pet cancer therapeutics market over the forecast period. Growing number of research grants to launch various anti-cancer therapies for veterinary cancer treatment is anticipated to be a major factor fueling growth of the global pet cancer therapeutics market in near future. For instance, in 2017, Animal Cancer Foundation had received a USD 1 million grant from the Blue Buffalo Foundation to support comparative oncology research, which aimed to study similarities between naturally occurring cancers in people & pets and find effective treatment in both species.
Furthermore, rise in the prevalence of cancer indicates a need to adopt approved novel therapies, which are proved to be highly effective for the treatment of cancers in pets, thus, propelling the pet cancer therapeutics market growth during the forecast period. As per the study by Fetch a Cure (2015), dogs & cats have a higher incidence of tumors than humans, where dogs are 35 times more likely to develop skin cancer, 4 times more likely to develop breast tumors, and 8 times more likely to develop bone cancer.
Market Restraints
Various side effects related to pet cancer therapeutics may hamper the growth of the pet cancer therapeutics market. Akin to humans, dogs & cats also suffer from diarrhea, vomiting, dehydration, low white blood cell count, lethargy, and bladder irritation as the side effects of chemotherapy. In addition, radiotherapy to treat cancer leads to early & delayed side effects in companion animals, like redness, irritation/ulceration on the treated surface area, known as moist desquamation.
Market Segmentation
The Global Pet Cancer Therapeutics Market is segmented into therapy type such as Chemotherapy, Targeted Therapy, Combination Therapy, Immunotherapy, etc. Further, market is segmented into pet type such as Cat, Dog, Horse.
Based on Route of Administration, Global Pet Cancer Therapeutics Market is segmented into Oral, Intravenous, and topical. On the basis of application, market is segmented into Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer, Others.
Regional Analysis
The Global Pet Cancer Therapeutics Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North American region is expected to dominate the pet cancer therapeutics throughout pertaining to rising pet adoption, rise in the occurrence of pet cancers, and presence of robust healthcare infrastructure facility as well as leading market players in the region.
Key Players
Various key players are discussed into the Global pet cancer therapeutic Market Report including: Zoetis, Inc., Elanco Animal Health, Boehringer Ingelheim International GmbH, Dechra Pharmaceuticals, AB Science, Qbiotics, NovaVive, Inc., ELIAS Animal Health, etc.
Market Taxonomy
By Therapy Type
By Pet Type
By Mode of Administration
By Application
By Region
Global Pet Cancer Therapeutics Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Pet Cancer Therapeutics Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Pet Cancer Therapeutics Market, By Therapy Type
5.1 Y-o-Y Growth Comparison, By Therapy Type
5.2 Global Pet Cancer Therapeutics Market Share Analysis, By Therapy Type
5.3 Global Pet Cancer Therapeutics Market Size and Forecast, By Therapy Type
5.3.1 Chemotherapy
5.3.2 Targeted Therapy
5.3.3. Combination Therapy
5.3.4. Immunotherapy
6 Global Pet Cancer Therapeutics Market, By Pet Type
6.1 Y-o-Y Growth Comparison, By Pet Type
6.2 Global Pet Cancer Therapeutics Market Share Analysis, By Pet Type
6.3 Global Pet Cancer Therapeutics Market Size and Forecast, By Pet Type
6.3.1 Cat
6.3.2. Dog
6.3.3. Horse
7 Global Pet Cancer Therapeutics Market, By Route of Administration
7.1 Y-o-Y Growth Comparison, By Route of Administration
7.2 Global Pet Cancer Therapeutics Market Share Analysis, By Route of Administration
7.3 Global Pet Cancer Therapeutics Market Size and Forecast, By Route of Administration
7.3.1 Oral
7.3.2 Intravenous
7.3.3. Topical
8 Global Pet Cancer Therapeutics Market, By Application
8.1 Y-o-Y Growth Comparison, By Application
8.2 Global Pet Cancer Therapeutics Market Share Analysis, By Application
8.3 Global Pet Cancer Therapeutics Market Size and Forecast, By Application
8.3.1. Lymphoma
8.3.2 Mast Cell Cancer
8.3.3 Melanoma
8.3.4 Mammary and Squamous Cell Cancer
8.3.5 Others
9 Global Pet Cancer Therapeutics Market, By Region
9.1 Global Pet Cancer Therapeutics Market Share Analysis, By Region
9.2 Global Pet Cancer Therapeutics Market Share Analysis, By Region
9.3 Global Pet Cancer Therapeutics Market Size and Forecast, By Region
10 North America Pet Cancer Therapeutics Analysis and Forecast (2022 – 2027)
10.1 Introduction
10.2 North America Pet Cancer Therapeutics Product Market Share Analysis, By Therapy Type
10.3 North America Pet Cancer Therapeutics Product Market Size and Forecast, By Pet Type
10.4 North America Pet Cancer Therapeutics Product Market Size and Forecast, By Route of Administration
10.5 North America Pet Cancer Therapeutics Product Market Size and Forecast, By Application
10.6 North America Pet Cancer Therapeutics Product Market Size and Forecast, By Country
10.6.1 U.S.
10.6.2 Canada
10.6.3 Mexico
11 Europe Pet Cancer Therapeutics Market Analysis and Forecast (2022 – 2027)
11.1 Introduction
11.2 Europe Pet Cancer Therapeutics Product Market Share Analysis, By Therapy Type
11.3 Europe Pet Cancer Therapeutics Product Market Size and Forecast, By Pet Type
11.4 Europe Pet Cancer Therapeutics Product Market Size and Forecast, By Route of Administration
11.5 Europe Pet Cancer Therapeutics Product Market Size and Forecast, By Application
11.6 Europe Pet Cancer Therapeutics Product Market Size and Forecast, By Country
11.6.1 Germany
11.6.2 France
11.6.3 UK
11.64. Rest of Europe
12 Asia Pacific Pet Cancer Therapeutics Market Analysis and Forecast (2022 – 2027)
12.1 Introduction
12.2 Asia Pacific Pet Cancer Therapeutics Product Market Share Analysis, By Therapy Type
12.3 Asia Pacific Pet Cancer Therapeutics Product Market Size and Forecast, By Pet Type
12.4 Asia Pacific Pet Cancer Therapeutics Product Market Size and Forecast, By Route of Administration
12.5 Asia Pacific Pet Cancer Therapeutics Product Market Size and Forecast, By Application
12.6 Asia Pacific Pet Cancer Therapeutics Product Market Size and Forecast, By Country
12.6.1 China
12.6.2 Japan
12.6.3 India
12.6.4. Rest of Asia Pacific
13 Latin America Pet Cancer Therapeutics Market Analysis and Forecast (2022 – 2027)
13.1 Introduction
13.2 Latin America Pet Cancer Therapeutics Product Market Share Analysis, By Therapy Type
13.3 Latin America Pet Cancer Therapeutics Product Market Size and Forecast, By Pet Type
13.4 Latin America Pet Cancer Therapeutics Product Market Size and Forecast, By Route of Administration
13.5 Latin America Pet Cancer Therapeutics Product Market Size and Forecast, By Application
13.6 Latin America Pet Cancer Therapeutics Product Market Size and Forecast, By Country
13.6.2. Rest of Latin America
14 Middle East Pet Cancer Therapeutics Market Analysis and Forecast (2022 – 2027)
14.1 Introduction
14.2 Middle East Pet Cancer Therapeutics Product Market Share Analysis, By Therapy Type
14.3 Middle East Pet Cancer Therapeutics Product Market Size and Forecast, By Pet Type
14.4 Middle East Pet Cancer Therapeutics Product Market Size and Forecast, By Route of Administration
14.5 Middle East Pet Cancer Therapeutics Product Market Size and Forecast, By Application
14.6 Middle East Pet Cancer Therapeutics Product Market Size and Forecast, By Country
14.6.2. UAE
14.6.3. Egypt
14.6.4 Kuwait
14.6.5. South Africa
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1 Zoetis, inc
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 Elanco Animal Health
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3 Boehringer Ingelheim International GmbH
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Dechra Pharmaceuticals
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 AB Science
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 Qbiotics
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 NovaVive, Inc
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8 ELIAS Animal Health
16.8.1 Overview
16.8.2 Offerings
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
